Samsung Bioepis Outlines European Eculizumab Roll-Out

Epysqli Rival To Soliris Is First Biosimilar Solely Commercialized By Firm In Europe

 
• By Dave Wallace

Samsung Bioepis has offered details on the launch of its Epysqli eculizumab biosimilar rival to Soliris in European markets.

Europe at night seen from space
Samsung Bioepis has started selling Epysqli in European markets • Source: Shutterstock

More from Biosimilars

More from Products